US equities
|
MU
$808.49
▼-5.45%
AMD
$484.30
▲+0.08%
AAPL
$353.88
▲+6.62%
NVDA
$203.76
▼-1.42%
MSFT
$555.50
▲+6.62%
AMZN
$268.51
▲+7.11%
META
$630.12
▲+1.46%
TSLA
$389.10
▼-2.36%
MU
$808.49
▼-5.45%
AMD
$484.30
▲+0.08%
AAPL
$353.88
▲+6.62%
NVDA
$203.76
▼-1.42%
MSFT
$555.50
▲+6.62%
AMZN
$268.51
▲+7.11%
META
$630.12
▲+1.46%
TSLA
$389.10
▼-2.36%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Today 9:15 EST
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
November 02, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
October 30, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Third Quarter 2026 Financial Results
October 29, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
October 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
October 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
October 19, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
October 15, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
September 16, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
September 15, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
September 08, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
August 27, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
August 26, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
August 24, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
August 04, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
July 24, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
July 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
MRK
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
July 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
June 24, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
June 23, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
June 15, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
June 12, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
June 11, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 08, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
MRK
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
June 05, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
June 04, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
LKFT
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
June 02, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
May 27, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
May 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
